The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the vaccine technology continue to play out on several other fronts. Pfizer and ...

First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe Strong immune response against all tested variants of concern Ready to supply for fall-winter COVID-19 ...

Drugmaker GSK will be paid up to £372m after settling a patent row over Covid vaccines in the US. The London-listed pharmaceuticals giant – previously known as Glaxosmithkline – and German partner ...

Settlement reached over mRNA-based COVID vaccines CureVac and GSK get $740 million upfront, and royalties BioNTech's deal to buy CureVac on track GSK's own lawsuits against Pfizer, BioNTech unaffected ...

Oct 28 (Reuters) - Britain's GSK (GSK.L), opens new tab cautioned full-year earnings would likely come in at the lower end of its forecast range after the COVID-19 pandemic took a toll on its vaccines ...

(Reuters) – GlaxoSmithKline Plc and Vir Biotechnology said on Monday final results from a late-stage study of their monoclonal antibody confirmed it significantly reduced hospitalization and death ...

LONDON -Activist investor Elliott said GlaxoSmithKline should review its leadership and consider a sale of its consumer ...

The New York powerhouse has agreed to surrender its 11.7% interest in the HIV-focused company for $1.875 billion. Under terms ...